Rachel Theriault, MD
Medical Oncology · Ft Worth, TXNPI 1780822478
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $731 of the $844 with a category attached, or 86.6%. It is spread thinly across 12 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 29 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$187
- Tempus AI, Inc$183
- Sirtex Medical Inc$112
- Lilly USA, LLC$103
- Sanofi$49
- Merck$49
- plus $162 from 6 others
Across 88 payments — averaging $1172.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$51K
- Pfizer$37K
- Sanofi US Services Inc.$11K
- AstraZeneca$4K
What the payments were for
- Food & beverage$73187%
- Education$11313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 7 | $187 |
| Tempus AI, Inc | 5 | $183 |
| Sirtex Medical Inc | 1 | $112 |
| Lilly USA, LLC | 2 | $103 |
| Sanofi | 3 | $49 |
| Merck | 2 | $49 |
| Novartis | 2 | $42 |
| GSK | 2 | $35 |
| Array Biopharma Inc | 1 | $30 |
| AstraZeneca | 2 | $29 |
| Seagen Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$844 in reported general payments places this provider in the 25th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BraftoviEncorafenib | 11 | $158,496 |
| EliquisApixaban | 44 | $26,618 |
| XareltoRivaroxaban | 26 | $23,255 |
| Anastrozole | 293 | $4,419 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 72 | $4,303 |
| Tamoxifen Citrate | 29 | $815 |
| Letrozole | 51 | $789 |
| Alendronate Sodium | 71 | $493 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $442 |
| Ibandronate Sodium | 13 | $427 |
| Oxycodone Hcl | 12 | $414 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $412 |
| Gabapentin | 53 | $397 |
| Hydroxyurea | 27 | $377 |
| Methadone Hcl | 12 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Array Biopharma IncBraftovi | $30 | $158,49611 claims |
| Lilly USA, LLCOlanzapine | $103 | $6313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Ft Worth
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.